Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2011-03-16 | JAMES C. MULLEN: Age 52; Principal Occupation: Chief Executive Officer of Patheon Inc., a global provider of contract development and manufacturing services to the pharmaceutical and biotechnology industries based in Toronto, Canada. Director of PerkinElmer since 2004. Chair of the nominating and corporate governance committee and a member of the compensation and benefits committee. |
| 2012-03-14 | James C. Mullen: Age 53; Principal Occupation: Chief Executive Officer of Patheon Inc., a global provider of contract development and manufacturing services to the pharmaceutical and biotechnology industries based in Toronto, Canada. Director of PerkinElmer since 2004. Chair of the nominating and corporate governance committee and a member of the compensation and benefits committee. |
| 2013-03-13 | James C. Mullen Age 54; Principal Occupation: Chief Executive Officer of Patheon Inc., a global provider of contract development and manufacturing services to the pharmaceutical and biotechnology industries based in Toronto, Canada. Director of PerkinElmer since 2004. Member of the audit and compensation and benefits committees. |
| 2014-03-12 | James C. Mullen, Age 55; Principal Occupation: Chief Executive Officer of Patheon Inc. Director of PerkinElmer since 2004. Member of the audit and compensation and benefits committees. 2013 Director Compensation: $235,014 total. |
| Filing Date | Source Excerpt |
|---|---|
| 2019-04-09 | Former Chief Executive Officer, Patheon N.V. and Former Chief Executive Officer, Biogen Inc. |
| 2020-04-07 | Mr. Mullen brings valuable industry knowledge to the Board, due to his 35 years of extensive management experience. |
| 2021-04-08 | Chairman, President and Chief Executive Officer of Editas Medicine, Inc. |
| 2022-04-07 | Chairman, President and Chief Executive Officer of Editas Medicine, Inc. |
| 2024-04-09 | Mr. Mullen previously served as Executive Chair of the Board of Directors of Editas Medicine. |
Data sourced from SEC filings. Last updated: 2025-07-01